1. Home
  2. ACRS vs MTW Comparison

ACRS vs MTW Comparison

Compare ACRS & MTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

N/A

Current Price

$3.90

Market Cap

868.5M

Sector

Health Care

ML Signal

N/A

Logo Manitowoc Company Inc. (The)

MTW

Manitowoc Company Inc. (The)

N/A

Current Price

$21.25

Market Cap

749.4M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
ACRS
MTW
Founded
2012
1902
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Construction/Ag Equipment/Trucks
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
868.5M
749.4M
IPO Year
2015
1994

Fundamental Metrics

Financial Performance
Metric
ACRS
MTW
Price
$3.90
$21.25
Analyst Decision
Strong Buy
Strong Sell
Analyst Count
12
2
Target Price
$10.18
★ $14.00
AVG Volume (30 Days)
★ 3.6M
423.0K
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 69.01
N/A
EPS
N/A
★ 0.22
Revenue
$1,683,000.00
★ $2,240,900,000.00
Revenue This Year
N/A
$3.43
Revenue Next Year
N/A
$1.55
P/E Ratio
★ N/A
$98.73
Revenue Growth
N/A
★ 2.89
52 Week Low
$1.74
$9.93
52 Week High
$6.60
$24.00

Technical Indicators

Market Signals
Indicator
ACRS
MTW
Relative Strength Index (RSI) 33.30 48.05
Support Level $3.16 $21.14
Resistance Level $4.63 $21.42
Average True Range (ATR) 0.41 0.96
MACD -0.15 -0.24
Stochastic Oscillator 28.38 2.26

Price Performance

Historical Comparison
ACRS
MTW

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

About MTW Manitowoc Company Inc. (The)

Manitowoc Co Inc provides engineered lifting solutions. It designs and manufactures mobile telescopic cranes, tower cranes, lattice-boom crawler cranes, and boom trucks. It offers products under brand names such as Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Manitowoc Crane Care. Its crane products serve dealers, rental companies, contractors, and government entities in diverse markets, including energy production/distribution and utility, petrochemical and industrial, infrastructure, and commercial/residential construction. Manitowoc has three reportable segments: the Americas, Europe and Africa, and the Middle East and Asia-Pacific. The Americas segment generates the majority of the revenue for the company.

Share on Social Networks: